Morning Industry Symposium:
Time to start CDK4&6 inhibition in EBC: Verzenio in HR+ HER2- node positive EBC at high risk of recurrence

Supported by Lilly

Saturday, October 15, 2022                                                                                                                                                                         Hall B (Great Hall 2)
Breakfast will be served from 07:00-07:30, half an hour prior to the start of the session.
Admission to this symposium is included as part of the congress registration.

Chairperson: Richard de Boer, Melbourne, Australia
07:30-07:50 Verzenio’s efficacy in node positive early breast cancer at high risk of recurrence
Alistair Ring, London, UK
07:50-08:10 Verzenio safety and tolerability: Learnings from MonarchE and food tolerability study
Fran Boyle, Sydney, Australia
A Verzenio EBC case study to open panel discussion
Catherine Shannon, Brisbane, Australia
Panel discussion + Q&A from audience
Skip to content